Company Description
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia.
Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.
Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Oct 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Pavel Raifeld |
Contact Details
Address: 1350 Old Bayshore Highway Burlingame, Delaware 94010 United States | |
| Phone | 650 238 9600 |
| Website | inva.com |
Stock Details
| Ticker Symbol | THRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001745020 |
| CUSIP Number | 88369M101 |
| ISIN Number | US88369M1018 |
| Employer ID | 83-0712806 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iain D. Dukes DPHIL, M.A. | Co-Founder and Chairman |
| Bradford D. Dahms | President, Chief Financial Officer and Director |
| Kristine Callahan CPA | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC TO-T/A | Filing |
| Feb 14, 2024 | SC 14D9/A | Filing |
| Feb 14, 2024 | 25-NSE | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 14D9/A | Filing |
| Feb 7, 2024 | SC TO-T/A | Filing |